Is DXCM stock a Buy, Sell, or Hold?

Based on our analysis, DXCM is currently a HOLD with moderate confidence. 📊 HOLD: DXCM is fairly valued with market pricing in 2.4% annual growth. Fine to hold or accumulate slowly on dips.

What is the fair value of DXCM stock?

Our analysis estimates the fair value range for DXCM to be between $84.52 and $88.93. The current price is $84.11.

What is the analyst price target for DXCM?

The average Wall Street analyst price target for DXCM is $96.23. This implies a potential upside of 14.4% from current levels.

DexCom (DXCM) Stock: Buy, Sell, or Hold?

DXCM - DexCom, Inc.

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

$84.11

-0.30 (-0.36%) ▼

5d: -1.46%

30d: -0.47%

90d: +10.16%

HOLD

MODERATE Confidence

Protect Your DXCM Gains

Analysis Updated: Oct 9, 2026 12:00 AM ET

Earnings: Oct 29, 2026 17d

Smart Money Accumulation

Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →

Signal fired Oct 6, 2026 at $83.39 · last confirmed Oct 7, 2026

Strength: 6.2/10

Get Alerted When DXCM Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.

100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading historical data...

💡

Bottom Line:
📊 HOLD: DXCM is fairly valued with market pricing in 2.4% annual growth. Fine to hold or accumulate slowly on dips.

See Forward Earnings Fair Value & Price Prediction →

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

Adjust Growth Assumption: 17.4%

0% (Stagnation) 50% (Hyper Growth)

EST. PRICE IN 2031

$129.36

Based on 10.7% avg growth

INTRINSIC VALUE TODAY

$80.32

Trading above historical range

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.

View Full DCF Model

In-depth Analysis How we analyze

Valuation Analysis: DXCM is currently trading at $84.11, which is considered oversold relative to its 30-day fair value range of $84.52 to $88.93. The stock's valuation (Forward PE: 26.9) is in line with its historical norms (25.0). At these levels, the market is pricing in 2.4% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.

Technical Outlook: Technically, DXCM is in a strong uptrend. The price is currently testing key support at $82.86. A bounce from this level would confirm strength, while a break below could signal further downside.

Market Sentiment: The stock scores a mixed 59/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $96.23 (+14.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.

Quick Decision Summary

Current Position OVERSOLD

Historical Trading Range $84.52 - $88.93

Company Quality Score 55/100 (HOLD)

Volume Confirmation HIGH

Confidence Score 78.1%

Protect Your Profits

Holding DXCM? Use our AI-powered strategies to protect your downside while keeping your long-term position.

View Profit Protection Plan

All Signals

BULLISH: Price oversold vs 30-day range
NEUTRAL: Mixed technical signals (59/100)
BULLISH: High volume confirmation
BULLISH: Trading below Wall St target ($96.23)
NEUTRAL: Market pricing in 2.4% annual earnings growth - fairly valued
NEUTRAL: Bottoming setup forming (59/100) — watch for confirmation

Trading Range Analysis

30-Day Trading Range $84.52 - $88.93

Current vs Trading Range OVERSOLD

Support & Resistance Levels

Support Level $82.86

Resistance Level $87.70

Current Trend Strong Uptrend

Technical data as of Oct 9, 2026

Fundamental Context

Forward P/E (Next Year Est.) 26.90

Wall Street Target $96.23 (+14.4%)

Revenue Growth (YoY) 13.1%

Earnings Growth (YoY) 43.6%

Profit Margin 20.1%

Valuation Premium vs History +2.4% premium

PE vs Historical 26.9 vs 25.0 FAIR

Market-Implied Price Targets If current PE multiple persists

Implied Growth (YoY): +2.4% (market-implied from PE analysis)

1-Year Target $86.13 (+2%)

2-Year Target $88.20 (+5%)

3-Year Target $90.31 (+7%)

3-Yr Target (if PE normalizes) (PE: 27→25) PE COMPRESSION $83.94 (0%)

Earnings growth offset by PE compression

3-Year Scenarios Using analyst projected EPS growth

Bull: (PE: 26.9, Growth: 17.4%) $135.98 (+62%)

Base: (SPY PE: 19.9, Growth: 17.4%) $100.40 (+19%)

Bear: (PE: 16.9, Growth: 17.4%) $85.34 (+2%)

📈 Valuation based on Current Earnings

RECOVERY PLAY: Stock looks expensive now (34x PE), but valuation improves significantly next year (27x PE) as earnings recover.

Trailing PE: 33.50 | Current EPS (TTM): $2.52

Bull Case $115.21 (+37%)

Analyst growth 24.1%, PE expands to 36.9

Base Case $104.74 (+25%)

Market implied 24.1%, PE stable at 33.5

Bear Case $57.40 (-32%)

Severe decline -20.0%, PE contracts to 28.5

These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.

Share & Embed Analysis

Found this analysis useful? Share it with your community or embed the live chart on your blog.

Tweet Reddit

bloggers & journalists: you are free to use our charts with attribution.

Last updated: October 11, 2026 9:37 AM ET
Data refreshes hourly during market hours. Next update: 10:37 AM

🔥 Top Stocks Breaking Out Now

Ticker	Score	Recommendation	Change %

See Full Scanner Results »

Technical Signals Check

Is DXCM showing a specific setup today?

RSI Divergence Check TTM Squeeze Check MACD Crossover Check Gamma Walls Check Unusual Activity Check

Insider Activity (6 Months)

Buys

Sells

Net

INSIDERS SELLING

Recent Transactions

Michael Jon Brown SELL 1700 shares 2026-04-15

View Insider Activity Scanner

Unlock Insider Activity

See real-time buying/selling by company executives for DXCM.

Create Free Account

Already have an account? Log In

Top Rated Medical Devices Stocks

Top-rated stocks in Medical Devices by analyst ratings.

Stock	Analyst Consensus	Analyst Target	Tradestie Score
ABT Abbott Laboratories	STRONG BUY 28 analysts	$121	60 BUY
MDT Medtronic PLC	BUY 29 analysts	$104	71 BUY
SYK Stryker Corporation	STRONG BUY 29 analysts	$364	52 HOLD
EW Edwards Lifesciences Corp	STRONG BUY 29 analysts	$102	49 HOLD
GEHC GE HealthCare Technologi…	STRONG BUY 21 analysts	$83	60 HOLD

ABT Abbott Laboratori…

60 BUY

MDT Medtronic PLC

71 BUY

SYK Stryker Corporati…

52 HOLD

EW Edwards Lifescien…

49 HOLD

GEHC GE HealthCare Tec…

60 HOLD

Advanced DXCM Option Strategies

Professional options setups generated by AI based on today's DXCM price and gamma walls.

Iron Condor Bull Call Bear Put Collar

More Analysis for DXCM

DXCM Technical Chart DXCM Price Prediction DXCM Earnings Date DXCM Investment Advisor DXCM Fair Price Analyzer DXCM Options Advisor DXCM Options Chain DXCM Options Analysis DXCM Competitors

Compare DXCM with Peers

DXCM vs PODD
Which one to buy?

DXCM vs IDXX
Which one to buy?

DXCM vs ALGN
Which one to buy?

DXCM vs VEEV
Which one to buy?

DXCM vs VRTX
Which one to buy?

ADSK vs DXCM
Winner: ADSK

IDXX vs DXCM

VTAK vs DXCM

Create New Comparison View All Competitors

Tradestie